Galectin-3 levels were significantly associated with markers of subclinical atherosclerosis and early cardiac dysfunction in patients with PCOS. Galectin-3 demonstrated potential utility as a biomarker for the early identification of subclinical atherosclerosis and heart failure risk in this population. Notably, this study is the first to evaluate the association of galectin-3 with both A-IMT and GLS in patients with PCOS, providing novel insights into their cardiovascular risk profile.
Erdem et al. (Tue,) studied this question.